Patient-Reported Outcome Measures and Patient Engagement in Heart Failure Clinical Trials: Multi-Stakeholder Perspectives
Key result
Patient-reported outcome measures are vital in heart failure care and drug development, requiring further standardization and research to define minimal clinically important differences.
Why the study?
Heart failure consequences substantially impact patients' lives but are not routinely captured in clinical trials, highlighting the need to improve the use of patient-reported outcomes.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support PRO integration in HF care and trials; leaves open optimal standardization and implementation.
Key Points
- The aim is to evaluate how patient-reported outcomes can enhance heart failure clinical trials and inform patient care.
- Involvement of various stakeholders, including patients and caregivers, in developing PROMs.
- Focus on improving data collection and analysis of PRO measures in both clinical trials and practice.
- Standardization of PROM instruments and reporting procedures to better reflect patient experiences.
- Identified a substantial gap in capturing health-related quality of life and functional status in clinical trials.
- Emphasized the need for routine PRO data collection to improve treatment responses and clinical decision-making.
- Outlined areas requiring further research to define minimal clinically important differences for various PROMs.
Structured PICO
P
Population
Patients with heart failure
I
Intervention
Patient-reported outcome measures (PROMs) and patient engagement
Patient-reported outcomes are vital in heart failure care and drug development, requiring standardization, patient involvement, and routine collection in trials and practice.
Cite This Study
Zannad et al. (2023) conducted a review in Heart failure. Patient-Reported Outcome Measures was evaluated. Patient-reported outcome measures are vital in heart failure care and drug development, requiring further standardization and research to define minimal clinically important differences.